Physician profile
Peter B Forman
NPI 1669084547
$10,086.72
in general payments reported to CMS, 2019-2025
26 companies · $1,941 in 2025
The $1,941 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,568 · 2022: $2,169 · 2023: $1,566 · 2024: $2,844 · 2025: $1,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,336 · Travel and Lodging: $1,666 · Consulting Fee: $280 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,336.29 |
| Travel and Lodging | $1,666.11 |
| Consulting Fee | $280.00 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,364.43 | 2022-2025 | Interstim |
| Axonics, INC. | $1,277.82 | 2021-2024 | Axonics |
| Teleflex LLC | $1,141.04 | 2021-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $1,021.24 | 2021-2025 | Myrbetriq, Xtandi |
| Sumitomo Pharma America, INC. | $783.53 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $455.10 | 2023-2025 | Erleada, Carvykti, Rybrevant |
| Endo USA, INC. | $385.23 | 2024-2025 | Xiaflex, Aveed |
| Boston Scientific Corporation | $345.00 | 2021-2025 | Lithovue, Spaceoar Vue System - 10ml, Rezum Generator |
| Urogen Pharma, INC. | $337.92 | 2023-2025 | Jelmyto |
| Urovant Sciences INC | $325.24 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $248.99 | 2022-2024 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $182.02 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.18 | 2022-2025 | |
| Tempus Ai, INC | $155.17 | 2024 | |
| Abbvie INC. | $132.64 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $124.39 | 2025 | Rivfloza |
| Amgen INC. | $121.72 | 2021 | |
| Myovant Sciences INC. | $102.02 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $94.28 | 2022 | |
| Dendreon Pharmaceuticals LLC | $84.15 | 2021 | |
| Myriad Genetic Laboratories, INC. | $83.18 | 2021-2024 | Prolaris |
| Astrazeneca Pharmaceuticals LP | $72.77 | 2024 | Airsupra |
| Tolmar Pharmaceuticals, INC. | $19.78 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.07 | 2022 | |
| Tolmar, INC. | $17.03 | 2024 | |
| Merck Sharp & Dohme LLC | $14.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Forman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.